Entrada Therapeutics, Inc.
NASDAQ:TRDABiotechnology
+$0.03 today
- Market cap
- $196.93M
- Beta
- -0.26
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$3.97
Volume 0.82M
Average 0.36M
TRDA EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Entrada Therapeutics, Inc.NASDAQ: TRDA
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$38.87M, compared with -$16.4M a year earlier. Trailing-twelve-month EBITDA was -$164.87M.
Context
- EBITDA amounted to 560.2% of revenue in FY2025, up 526.8 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 4 analysts of -$163.49M (-14.8%) for the fiscal year ending Dec 2026, a step up from the -302.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$38.87M+7.1% QoQ
- Last fiscal yearDec 2025
- -$142.4M-302.7% YoY
- LTMMar 2026
- -$164.87M-697.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -137.0% | -4.1% | +132.9 pp |
| 1 year | -302.7% | -14.8% | +287.9 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (142.4M) USD
- Year-over-year change
- -302.7%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (142.4M) | -302.7% |
| FY2024 | 2024-12-31 | 70.26M | +371.6% |
| FY2023 | 2023-12-31 | 14.9M | +116.5% |
| FY2022 | 2022-12-31 | (90.09M) | -80.0% |
| FY2021 | 2021-12-31 | (50.04M) | — |
EBITDA vs competitors
How TRDA compares with its peers on the latest reported figures
- TRDA's LTM Mar 2026 EBITDA of -$164.87M is the 10th highest of the 11 companies compared; the peer median is -$73.65M.
- Its year-over-year change of -697.5% is the lowest of 11, against a peer median of -9.1%.
- EBITDA amounts to 2873.3% of revenue for TRDA, versus a peer median of 228.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $893.33M | +1767.7% | — | — | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | -$46.14M | +19.2% | — | — |
| LTM Mar 2026 | -$50.86M | -14.6% | — | — | |
| LTM Mar 2026 | -$58.85M | +7.0% | — | — | |
| LTM Mar 2026 | -$67.53M | -3.7% | — | 148.9% | |
| LTM Mar 2026 | -$79.77M | -33.1% | — | 3956.7% | |
| LTM Mar 2026 | -$112.54M | -37.5% | — | 308.4% | |
| LTM Mar 2026 | -$136.24M | -213.5% | — | 62.6% | |
| LTM Mar 2026 | -$160.41M | +32.7% | — | — | |
| LTM Mar 2026 | -$164.87M | -697.5% | — | 2873.3% | |
| LTM Mar 2026 | -$179.89M | -30.1% | — | — | |
| Peer median (excluding TRDA) | -$73.65M | -9.1% | — | 228.6% | |
Competitors are the stored peer set for TRDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 129.01M | 210.78M | 25.42M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 4.1M |
| Gross Profit | 0 | 0 | 129.01M | 210.78M | 21.33M |
| Gross Margin | — | — | 100.0% | 100.0% | 83.9% |
| Research & Development | 35.93M | 66.61M | 99.88M | 125.31M | 142.27M |
| Selling, General & Admin | 15.2M | 30.64M | 32.29M | 38.47M | 41.05M |
| Operating Expenses | 51.13M | 97.25M | 132.18M | 163.77M | 177.32M |
| Depreciation & Amortization | 1.12M | 1.9M | 2.84M | 3.77M | 425K |
| EBITDA | (50.04M) | (90.09M) | 14.9M | 70.26M | (142.4M) |
| EBITDA Margin | — | — | 11.5% | 33.3% | -560.2% |
| Operating Income | (51.13M) | (97.25M) | (3.16M) | 47.01M | (156M) |
| Operating Margin | — | — | -2.5% | 22.3% | -613.7% |
| Interest Income | 0 | 2.63M | 15.22M | 19.47M | 0 |
| Interest Expense | 0 | 2.63M | 0 | 0 | 0 |
| Other Income / Expenses | (31K) | 2.63M | 15.22M | 19.47M | 13.17M |
| Income Before Tax | (51.16M) | (94.62M) | 12.06M | 66.49M | (142.83M) |
| Pre-Tax Margin | — | — | 9.3% | 31.5% | -561.8% |
| Income Tax Expense | 0 | 0 | 18.74M | 859K | 924K |
| Net Income | (51.16M) | (94.62M) | (6.69M) | 65.63M | (143.75M) |
| Net Margin | — | — | -5.2% | 31.1% | -565.5% |
| EPS (Basic) | (1.60) | (2.79) | (0.20) | 1.76 | (3.47) |
| EPS (Diluted) | (1.60) | (2.79) | (0.20) | 1.68 | (3.47) |
| Weighted Avg Shares | 31.22M | 31.29M | 33.05M | 37.31M | 41.37M |
| Weighted Avg Shares (Diluted) | 31.22M | 31.29M | 33.05M | 39M | 41.37M |
Entrada Therapeutics, Inc.
NASDAQ:TRDA
Intrinsic Alpha fair value
Locked
Current Price
$5.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.